Method for antiphospholipid syndrome

Details Method for antiphospholipid syndrome Method for antiphospholipid syndrome

2011-01-11

2011-01-11

Cook, Lisa V (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007100, C435S007950, C436S501000, C436S518000, C422S067000

Reexamination Certificate

active

07867723

ABSTRACT:
Methods for detecting anti-lipidic particle antibodies and lipidic particles in cellular membranes for the diagnosis of diseases associated with antiphospholipid syndrome are disclosed. Kits or sets to put these methods of diagnosis into practice are disclosed. Methods for the therapeutic treatment of diseases associated with antiphospholipid syndrome are disclosed as well. In addition, methods for the detection of the diverse physiologic states of cells and kits useful for this are also disclosed.

REFERENCES:
patent: 4444879 (1984-04-01), Foster et al.
patent: 4698299 (1987-10-01), Janoff et al.
patent: 5344758 (1994-09-01), Krillis et al.
patent: 5472883 (1995-12-01), Matsuura et al.
patent: 5506110 (1996-04-01), Matsuura et al.
patent: 5561070 (1996-10-01), Stewart et al.
patent: 5610024 (1997-03-01), Muller-Berghaus et al.
patent: 5776487 (1998-07-01), Wilson et al.
patent: 5780319 (1998-07-01), Wilson et al.
patent: 5840587 (1998-11-01), Stewart et al.
patent: 5998223 (1999-12-01), Matsuura et al.
patent: 6284475 (2001-09-01), Rand
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6824988 (2004-11-01), Roelens et al.
patent: 6824999 (2004-11-01), Robichaud et al.
Wilson, W.A. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999;42:1309-1311.
Ortiz, A. et al. Membrane fusion and the lamellar-to-inverted-hexagonal phase transition in cardiolipin vesicle systems induced by divalent cations. Biophys. J. 1999;77:2003-2014.
American College of Rheumatology, History of the ACR, available at <http://www.rheumatology.org> (last update unknown). p. 1 of 1.
Ramirez et al., Induccibn y Caracterizacibn de Anticuerpos Antifosfolipidos Obtenidos en Ratones BaIB/c Tratados con Cloropromacina, Procainamida y Liposomas, Instituto Politecnico Nacional, Mexico, D.F., 1998.
Aguilar et al., “Phospholipid Membranes Form Specific Nonbilayer Molecular Arrangements That Are Antigenic,” The Journal of Biological Chemistry 274(36):25193-25196, 1999.
Alving, “Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens,” Biochim. Biophys. Acta 1113:307-22, 1992.
Arvieux, “Development of an ELISA for Autoantibodies to Prothrombin Showing their Prevalence in Patients with Lupus Anticoagulants,” Thromb Haemost 74(4):1120-5, 1995.
Asherson et al., The Antiphospholipid Syndrome: History, Definition, Classification, and Differential Diagnosis, Chapter I, pp. 3-12, CRC Press, Inc., 1996.
Baeza et al., “Transbilayer Diffusion of Divalent Cations into Liposomes Mediated by Lipidic Particles of Phosphatidate,” J. Mol. Evol. 39:560-568, 1994.
Baeza et al., “Identification of phosphatidate nonlamellar phases on liposomes by flow cytometry,” Biochem. Cell Biol. 73:289-297, 1995.
Berard et al., “Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies,” J. Lab. Clin. Med. 122(5):601-605, 1993.
Bevers et al., “Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin,” Thromb Haemost 66(6):629-32, 1991.
Biasiolo et al., “Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis,” Blood Coagulation Fibrinolysis 4:425-428, 1993.
Cullis et al., “Lipid Polymorphism,” Membrane Fusion, pp. 35-64, Marcel Dekker, New York, 1991.
Faisal, “Detección de Anticuerpos Contra Particulas Lipídicas en el Suero de Pacientes con Síndrome de Antifosfolípidos,” Instituto Politecnico Nacional, Mexico, D.F., 1999.
Gibson et al., “CombinedD-Penicillamine and Chloroquine Treatment of Rheumatoid Arthritis—A Comparative Study,” Br J Rheumatol 26(4):279-84, 1987.
Guglielmone et al., Distribution of Lupus Anticoagulant and Anticardiolipin Antobidy Isotypes in a Population with Antiphospholipid Syndrome, The Journal of Rheumatology 26(1):86-90, 1999.
Harris et al., “Anti-phospholipid Antibodies,” Clinics in Rheumatic Diseases, 11(3):591-609, Dec. 1985.
Köhler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature 256:495-497, Aug. 7, 1975.
Loizou et al., “Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results,” Clin. exp. Immunol. 62:738-745, 1985.
McNeil et al., “Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics,” British Journal of Haematology 73:506-513, 1989.
McNeil et al., “Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-Glycoprotein I (apolipoprotein H),” Proc. Natl. Acad. Sci. USA 87:4120-4124, Jun. 1990.
Nakamura et al., “Lupus Anticoagulant Autoantibody Induces Apoptosis in Umbilical Vein Endothelial Cells: Involvement of Annexin V,” 205(2):1488-1493, Dec. 15, 1994.
Nilsson et al, “Immunization of mice and rabbits by intrasplenic deposition of nanogram quantities of protein attached to Sepharose beads or nitrocellulose paper strips,” Journal of Immunological Methods 99:67-75, 1987.
Pengo, “Autoimmune Antiphospholipid Antibodies Are Directed against a Cryptic Epitope Expressed when β2-Glycoprotein I is Bound to a Suitable Surface,” Thromb Haemost 73(1):29-34, 1995.
Pierangeli et al., “Are immunoglobulins with lupus anticoagulant activity specific for phospholipids?” British Journal of Haematology 85:124-132, 1993.
Piette et al., “Exclusion Criteria for Primary Antiphospholipid Syndrome,” The Journal of Rheumatology 20:1802-1804.
Pittoni et al., “Apoptosis and Antiphospholipid Antibodies,” Seminars in Arthritis and Rheumatism 28(3):163-178, Dec. 1998.
Ramirez, “Caracterizacion Fisica E Inmunologica de Arreglos Moleculares de No-Bicapa en Liposomas,” Instituto Politecnico Nacional, Mexico, D.F., 1994.
Ramirez et al., “Determinación de Asociaciones Lipídicas de No-Bicapa en Liposomas y Membranas Celulares con Anticuerpos Monoclonales,” Instituto Politecnico Nacional, Mexico, D.F., 1997.
Ramirez et al., Inducción y Caracterización de Anticuerpos Antifosfolipidos Obtenidos en Ratones BalB/c Tratados con Cloropromacina, Procainamida y Liposomas, Instituto Politecnico Nacional, Mexico, D.F., 1998.
Rauch et al., “Distinguishing Plasma Lupus Anticoagulants from Anti-Factor Antibodies Using Hexagona (II) Phase Phospholipids,” Thrombosis and Haemostasis 62(3):892-896, 1989.
Rauch et al., “Inhibition of Lupus Anticoagulant Activity by Hexagonal Phase Phosphatidylethanolamine in the Presence of Prothrombin,” Thromb Haemost 80:936-41, 1998.
Roubey et al., “‘Anticardiolipin’ Autoantibodies Recognize β2-Glycoprotein I in the Absence of Phospholipid,” Journal of Immunology pp. 954-960, 1995.
Schuber, “Influence of polyamines on membrane functions,” Biochem. J. 260:1-10, 1989.
Shi et al., β2-Glycoprotein I Is a Requirement for Anticardiolipin Antibodies Binding to Activated Platelets: Differences With Lupus Anticoagulants, Blood 81(5):1255-1262, Mar. 1, 1993.
Shoenfeld et al., “Lessons from experimental APS models,” Lupus 7 (Suppl. 2):S158-S161, 1998.
Sugi et al., “Autoantibodies to Phosphatidylethanolamine (PE) Recognize a Kininogen-PE Complex,” Blood 86(8):3083-9, Oct. 15, 1995.
Tan et al., “The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus,” Arthritis Rhem 25(11):1271-1277, Nov. 1982.
Tinc

Affiliated with

Also associated with

Rating

Method for antiphospholipid syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for antiphospholipid syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for antiphospholipid syndrome will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2741719